1707 ET - Exelixis's 1Q results crushed Wall Street's expectations after getting a boost from accelerating demand for its flagship Cabometyx cancer drug. Product revenue, composed almost entirely of Cabometyx sales, rose 36% in the quarter on higher volumes and prices, offsetting a 10% decline in collaboration revenues. The company expects such growth to continue, with its higher full-year outlook implying as much as 19% growth in product revenues from a year ago. Higher demand for the drug comes as it notches further support from the FDA, getting approval in March for treatment in previously treated advanced neuroendocrine tumors, adding to five previous approvals for the drug's use in other tumors. Shares rise 6.4% in after-hours trading. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
May 13, 2025 17:07 ET (21:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.